Log in to your Inderes Free account to see all free content on this page.
Hamlet BioPharma
5.62 SEK
+1.44 %
Less than 1K followers
HAMLET B
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+1.44 %
+4.27 %
-4.75 %
+14.23 %
-6.49 %
+36.41 %
+43.86 %
-11.32 %
+154.01 %
Hamlet BioPharma operates in the pharmaceutical industry. The company conducts drug development based on a tumor-killing protein-lipid complex, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that will primarily be used for the treatment and prevention of cancer diseases. Hamlet BioPharma was founded in 2015 and is headquartered in Lund.
Read moreMarket cap
1.04B SEK
Turnover
443.56K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
22.5.
2026
Interim report Q3'26
28.8.
2026
Annual report '26
13.11.
2026
Interim report Q1'27
All
Press releases
ShowingAll content types
Hamlet BioPharma AB (publ): Nature Microbiology publishes the paper `'Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.''
Hamlet BioPharma AB (publ): Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it's Q2 report
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio